Valuation: Lundbeck

Market Cap 41.51B 6.35B 5.55B 5.1B 4.76B 9.02B 605B 9.16B 61.27B 23.82B 297B 23.85B 23.33B 1,025B P/E 2026 *
9.49x
P/E 2027 * 9.31x
Enterprise Value 45.59B 6.98B 6.1B 5.61B 5.23B 9.91B 664B 10.06B 67.31B 26.17B 327B 26.2B 25.63B 1,126B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.6x
Free-Float
30.76%
Yield 2026 *
3.42%
Yield 2027 * 3.53%
1 day-1.60%
1 week-0.14%
Current month+0.82%
1 month-0.14%
3 months+8.53%
6 months-0.27%
Current year+1.93%
1 week 36.25
Extreme 36.25
37.75
1 month 35.65
Extreme 35.65
37.75
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-0.14% - - 6.51B
+2.37%+2.94%+11.46%+84.01% 92.06B
+0.51%+1.78%+47.51%+152.66% 55.96B
+2.20%-0.36%-6.69%+232.14% 21.77B
+1.26%+2.15%-9.49%-28.07% 7.88B
+1.90%+7.74%-25.08%-30.71% 7.61B
+1.89%+4.76%-9.51%-31.67% 6.54B
+0.17%+0.64%-1.59%+19.58% 5.36B
+1.86%+2.28%-3.52%-14.05% 3.56B
-1.31%+1.26%+13.27%+12.53% 3.41B
Average +0.90%+2.01%+1.82%+44.05% 22.68B
Weighted average by Cap. +1.53%+2.05%+15.99%+101.72%

Financials

2026 *2027 *
Net sales 25.74B 3.94B 3.44B 3.17B 2.95B 5.6B 375B 5.68B 38B 14.77B 184B 14.79B 14.47B 635B 25.82B 3.95B 3.45B 3.18B 2.96B 5.61B 376B 5.7B 38.12B 14.82B 185B 14.83B 14.52B 637B
Net income 4.75B 727M 635M 584M 544M 1.03B 69.2B 1.05B 7.01B 2.72B 34.01B 2.73B 2.67B 117B 4.83B 739M 646M 594M 554M 1.05B 70.41B 1.07B 7.13B 2.77B 34.61B 2.78B 2.72B 119B
Net Debt 4.09B 626M 547M 503M 469M 889M 59.6B 903M 6.04B 2.35B 29.3B 2.35B 2.3B 101B -93.58M -14.32M -12.52M -11.51M -10.73M -20.34M -1.36B -20.65M -138M -53.7M -670M -53.76M -52.61M -2.31B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
03/07/26 DKK 36.90 -1.60% 43,652
02/07/26 DKK 37.50 +2.74% 76,167
01/07/26 DKK 36.50 -0.27% 48,456
30/06/26 DKK 36.60 +0.55% 72,950
29/06/26 DKK 36.40 +0.14% 75,003
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
43.12DKK
Average target price
47.46DKK
Spread / Average Target
+10.06%

Quarterly revenue - Rate of surprise